Dr. Duke is a biotechnology executive, inventor, biomedical researcher and serial entrepreneur with nearly 20 years of experience in building, financing, and managing start-up biotechnology companies based on inventions made in Colorado’s non-profit research institutions. He is currently Founder and CSO of the Colorado Institute for Drug, Device and Diagnostic Development and is Co-scientific Founder and Acting President and CEO of ApopLogic Pharmaceuticals. Dr. Duke is a Co-scientific Founder and former CEO of GlobeImmune (Nasdaq: GBIM) and was involved in the formation and/or management of Newellink, Sierra Neuropharmaceuticals, MenoGeniX, PeptiVir and Aurora Oncology. These Colorado-based companies have raised more than $200 million in financing and have multiple products in phase 1 and 2 human clinical trials. In addition to his entrepreneurial activities, Dr. Duke has 30 years of experience in cutting-edge biomedical research and is a tenured faculty member in the Department of Medicine (Medical Oncology) at the University of Colorado Denver. His seminal work on apoptosis was recognized in the cover article of Scientific American in October 1996. Dr. Duke has provided independent 3rd party research analysis in the life sciences sector to Janus Capital and to venture capital firms. He is a graduate of McGill University (B.Sc. and M.Sc.) and the University of Colorado (Ph.D.). Dr. Duke strongly believes in the merits and opportunities that arise from building new companies based on University technologies and enjoys working with academic entrepreneurs.